Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

(2021) Hope S. Rugo et al.   JAMA Oncology

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

(2021) Rosalynd Upton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of Innate and Adaptive Immunity in the Efficacy of anti-HER2 Monoclonal Antibodies for HER2-positive Breast Cancer

(2020) Antonino Musolino et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

(2020) Roger B. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

(2019) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation

(2019) Daniela Pende et al.   Frontiers in Immunology

Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy

(2019) Deepak Mittal et al.   OncoImmunology

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

(2018) Martin Wermke et al.   JOURNAL OF CLINICAL ONCOLOGY

The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

(2018) Natasha A. Pereira et al.   mAbs

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

(2018) Hans H. Oberg et al.   Frontiers in Immunology

A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ

(2018) Hongtao Zhang et al.   OncoImmunology

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

(2018) Morten Mau Soerensen et al.   JOURNAL OF CLINICAL ONCOLOGY

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

(2018) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism

(2018) Niken M. Mahaweni et al.   Scientific Reports

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

(2018) Estefanía Paula Juliá et al.   Frontiers in Immunology

Natural Killer Cells: Development, Maturation, and Clinical Utilization

(2018) Alex M. Abel et al.   Frontiers in Immunology

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

(2017) Takahiro Ishiguro et al.   Science Translational Medicine

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

(2017) Andres Lopez-Albaitero et al.   OncoImmunology

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

(2017) Patrick G. Gavin et al.   JAMA Oncology

A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.

(2017) M. J. Higgins et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells

(2016) Y. Mao et al.   BLOOD

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

(2016) N. Haense et al.   BMC CANCER

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

(2016) Gábor Tóth et al.   mAbs

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)

(2016) Anja K. Wege et al.   Oncotarget

Blinatumomab

(2015) Larry W. Buie et al.   ANNALS OF PHARMACOTHERAPY

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

(2015) L. G. Lum et al.   CLINICAL CANCER RESEARCH

Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages

(2015) Yun Shi et al.   JOURNAL OF IMMUNOLOGY

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma

(2015) Mehrdad Talebian Yazdi et al.   Oncotarget

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential

(2014) Dorit Lehmann et al.   PLoS One

Association Studies of Fc  Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

(2014) N. Norton et al.   Cancer Immunology Research

Immune-suppressive properties of the tumor microenvironment

(2013) Jürgen C. Becker et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

scFv-Based "Grababody" as a General Strategy to Improve Recruitment of Immune Effector Cells to Antibody-Targeted Tumors

(2013) Z. Cai et al.   CANCER RESEARCH

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity

(2013) Hing C Wong et al.   OncoImmunology

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Analysis of Fc  Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

(2012) S. A. Hurvitz et al.   CLINICAL CANCER RESEARCH

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

(2012) P Glorius et al.   LEUKEMIA

Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell–activating cytokines

(2012) Eric Luedke et al.   SURGERY

Modulation of tumor immunity by therapeutic monoclonal antibodies

(2011) Riad Abès et al.   CANCER AND METASTASIS REVIEWS

Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)

(2011) M. Jager et al.   CANCER RESEARCH

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes

(2011) M. Gooden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

(2010) K. Tamura et al.   ANNALS OF ONCOLOGY

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

(2009) T. S. Bekaii-Saab et al.   MOLECULAR CANCER THERAPEUTICS

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies

(2008) W. Lin et al.   BLOOD

The “Other” Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs

(2008) Luca Gianni   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

(2008) Ignacio Melero et al.   TRENDS IN PHARMACOLOGICAL SCIENCES